AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. DYN
  4. [Form 4] Dyne Therapeutics, Inc. Insider Trading Activity

[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock DYN logo
Dyne Therapeutics, Inc.

NASDAQ:DYN

DYN Rankings

#3173 Ranked by Market Cap
N/A Ranked by Dividends

DYN Latest News

Aug 4, 2025
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
Jul 28, 2025
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Jul 16, 2025
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
Jul 2, 2025
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Jun 30, 2025
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

DYN Latest SEC Filings

Aug 4, 2025
[8-K] Dyne Therapeutics, Inc. Reports Material Event
Jul 28, 2025
[8-K] Dyne Therapeutics, Inc. Reports Material Event
Jul 28, 2025
[10-Q] Dyne Therapeutics, Inc. Quarterly Earnings Report
Jul 18, 2025
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity
Jul 18, 2025
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity

DYN Stock Data

1.41B
132.26M
0.49%
88.46%
11.06%
Biotechnology
Pharmaceutical Preparations
United States
WALTHAM